Compare SONO & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SONO | XNCR |
|---|---|---|
| Founded | 2002 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2018 | 2013 |
| Metric | SONO | XNCR |
|---|---|---|
| Price | $17.12 | $33.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $18.63 | ★ $43.83 |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 243.14 | 65.36 |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $1,546,890,000.00 | $125,576,000.00 |
| Revenue This Year | $6.93 | $58.19 |
| Revenue Next Year | $6.75 | N/A |
| P/E Ratio | $23.38 | ★ N/A |
| Revenue Growth | 7.18 | ★ 13.65 |
| 52 Week Low | $12.44 | $10.38 |
| 52 Week High | $19.82 | $40.60 |
| Indicator | SONO | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 54.03 |
| Support Level | $16.70 | $22.80 |
| Resistance Level | $17.19 | $33.60 |
| Average True Range (ATR) | 0.99 | 2.08 |
| MACD | -0.01 | -0.54 |
| Stochastic Oscillator | 40.87 | 35.21 |
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.